Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
06:20pm, Thursday, 30'th Jan 2025
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
12:00pm, Friday, 03'rd Jan 2025
Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
11:32am, Thursday, 26'th Dec 2024
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
02:21pm, Thursday, 19'th Dec 2024
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
06:38am, Thursday, 19'th Dec 2024
On Wednesday, the FDA approved Mesoblast Limited's MESO Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S.
Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
07:08pm, Wednesday, 18'th Dec 2024
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Admini
Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval
06:44pm, Wednesday, 18'th Dec 2024
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
04:58pm, Wednesday, 18'th Dec 2024
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-hos
Mesoblast to be Added to Nasdaq Biotechnology Index
07:30am, Wednesday, 18'th Dec 2024
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
06:32pm, Wednesday, 04'th Dec 2024
Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Earlier this year FDA granted REVASCOR both Rare Pe
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
06:20pm, Monday, 02'nd Dec 2024
Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy Phase 3 trial results published in European Journal of Heart F
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
07:11pm, Wednesday, 30'th Oct 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
04:24pm, Monday, 30'th Sep 2024
Mesoblast Limited is advancing innovative cellular therapies, with Remestemcel-L for pediatric SR-aGVHD nearing FDA approval and a PDUFA date set for January 2025. Positive Phase 3 results indicate th
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
08:55pm, Sunday, 29'th Sep 2024
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a c
Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript
09:04pm, Wednesday, 28'th Aug 2024
Mesoblast Limited (NASDAQ:MESO ) Q4 2024 Earnings Conference Call August 28, 2024 6:30 PM ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Andrew Chaponnel - Inter
